Itacitinib to Prevent Graft Versus Host Disease
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Itacitinib (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Tacrolimus; Thiotepa
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 12 Mar 2024 Planned number of patients changed from 30 to 31.
- 12 Mar 2024 Status changed from active, no longer recruiting to recruiting.
- 20 Feb 2024 Planned End Date changed from 2 Feb 2027 to 1 Apr 2025.